
Nexalin Technology, Inc.
100
Recent developments include Nexalin’s acquisition of an AI health platform to support its HALO Clarity pivotal trial, agreements to advance clinical trials, launch of pivotal trials for insomnia, expansion of peer-reviewed evidence, and corporate actions such as a reverse stock split to regain Nasdaq compliance.
- Nexalin acquired an AI health platform in May 2026 to support the HALO Clarity pivotal trial and enhance clinical research capabilities [N4].
- The company entered into an agreement with Lindus Health in April 2026 to advance the pivotal clinical trial of the HALO Clarity device [N5].
- Nexalin launched a pivotal HALO Clarity trial in February 2026 to support planned FDA submission for insomnia treatment [N6].
- The company expanded peer-reviewed evidence for its DIFS non-invasive brain stimulation technology in February 2026 [N7].
- Nexalin appointed Justin Van Fleet as CFO in August 2025 [N8].
- The company completed a one-for-thirty reverse stock split in August 2026 as part of efforts to regain Nasdaq minimum bid price compliance, which was confirmed in September 2026 [N2][N3].
Nexalin Technology, Inc. is a medical device company headquartered in Houston, Texas, focused on developing non-invasive neurostimulation devices to treat mental health and cognitive disorders. Its original Gen-1 device uses cranial electrotherapy stimulation (CES) technology emitting 4 milliamps and is FDA Class II for anxiety and insomnia treatment. The company is advancing next-generation devices, Gen-2 SYNC and Gen-3 HALO, which emit a proprietary 15 milliamp waveform designed for deeper brain stimulation and enhanced efficacy. These devices are undergoing FDA regulatory review through Q-submissions and pre-submission processes, with clinical trials planned or underway in the U.S., Brazil, and China. Nexalin is also developing a virtual clinic platform to enable tele-psychiatry diagnosis and prescription for home use of its devices. The company has regulatory approvals for its Gen-2 device in China, Brazil, and Oman, and has formed a joint venture for commercialization in China. Financially, Nexalin has limited revenue, recurring operating losses, and liquidity challenges, with recent corporate actions including a reverse stock split to regain Nasdaq compliance and acquisitions to enhance its AI health platform and clinical research capabilities.
Nexalin Technology, Inc. develops innovative neurostimulation medical devices targeting mental health disorders, including anxiety, insomnia, depression, Alzheimer's disease, and dementia. The company’s Gen-1 device is FDA Class II for anxiety and insomnia but requires new FDA approvals for marketing. Nexalin is advancing Gen-2 SYNC and Gen-3 HALO devices with proprietary 15 milliamp waveforms through FDA Q-submissions and clinical trials in multiple countries. The company is developing a virtual clinic platform for tele-psychiatry and home use of its devices. Nexalin has regulatory approvals in China, Brazil, and Oman, and a joint venture for China commercialization. Financially, as of September 30, 2026, Nexalin reported limited revenue, significant net losses, and liquidity ratios below 1. The company completed a reverse stock split to regain Nasdaq compliance but faces ongoing listing risks related to stockholders’ equity requirements. Nexalin acquired an AI health platform and licensed software to support clinical research and device commercialization. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. [S1][S2][N2][N3][N4][N5][N6][N7][N8]
Nexalin’s advanced 15 milliamp waveform technology and next-generation devices (Gen-2 SYNC and Gen-3 HALO) represent a potentially disruptive approach to treating mental health disorders non-invasively and without side effects. The company’s ongoing clinical trials and FDA interactions, including Q-submissions and pivotal studies for insomnia and Alzheimer’s disease, demonstrate progress toward regulatory clearance. The virtual clinic platform could reduce stigma and improve patient access through tele-psychiatry and home treatment. Regulatory approvals in China, Brazil, and Oman, along with a joint venture for regional commercialization, provide international market opportunities. The acquisition of an AI health platform and licensed software supports enhanced clinical research and device integration. If clinical and regulatory milestones are achieved, Nexalin could establish a differentiated position in the mental health treatment market.
Nexalin faces significant risks including regulatory uncertainty as its next-generation devices require FDA clearance through complex pathways such as 510(k), De Novo, or PMA submissions. Clinical trials may not demonstrate sufficient safety or efficacy to support approvals. The company has limited revenue and recurring net losses, with liquidity ratios below 1, indicating financial constraints. Continued compliance with Nasdaq listing requirements depends on meeting stockholders’ equity thresholds and maintaining minimum bid prices, with risks of delisting. The integration and commercialization of acquired AI health technology may face delays or fail to deliver anticipated benefits. Market acceptance of novel neurostimulation devices may be limited by competition, reimbursement challenges, and patient adoption barriers. Dilution from equity financings and outstanding warrants could impact shareholder value.
Nexalin’s moat is based on its proprietary bioelectronic waveform technology delivering non-invasive brain stimulation at 15 milliamps, which is more powerful than prior devices without causing discomfort or side effects. The company holds patents protecting its waveform and device design, including proprietary single-use electrodes with RFID tracking to ensure recurring revenue and prevent generic knockoffs. Its regulatory progress with the FDA through Q-submissions and clinical trials, along with approvals in China, Brazil, and Oman, provide barriers to entry. The development of a virtual clinic platform integrating tele-psychiatry and device monitoring adds a differentiated service layer. Strategic partnerships, including a joint venture in China and a Military & Government Advisory Board, further support market access. However, the company faces challenges typical of early-stage medical device firms, including regulatory risk, clinical validation, and capital requirements.
• Regulatory Approval Risk: Nexalin’s Gen-2 and Gen-3 devices require FDA clearance through Q-submissions, 510(k), De Novo, or PMA pathways. Failure to obtain timely or any clearance could delay or prevent commercialization in the U.S.
• Financial and Liquidity Risk: The company has limited revenue, significant net losses, and liquidity ratios below 1 as of September 30, 2026. It depends on equity and debt financings to fund operations and clinical trials, with risks of insufficient capital.
• Nasdaq Listing Compliance Risk: Nexalin’s continued Nasdaq listing depends on meeting minimum stockholders’ equity and bid price requirements. Failure to maintain compliance could result in delisting and reduced market liquidity.
• Clinical Trial and Commercialization Risk: Clinical trials may not demonstrate efficacy or safety sufficient for regulatory approval or market acceptance. Integration of acquired AI health platform technology may face development or operational challenges.
• Market Acceptance and Competition Risk: The neurostimulation device market is competitive and subject to reimbursement and adoption challenges. Patient stigma, alternative therapies, and technological advances by competitors may limit Nexalin’s market penetration.
Business trends: Continued advancement of proprietary neurostimulation devices targeting mental health disorders with expanding clinical trials and regulatory engagement.
Execution milestones: Progression of pivotal clinical trials for HALO Clarity, FDA Q-submissions, virtual clinic platform development, and integration of AI health platform technology.
Key risks: Regulatory approval uncertainty, financial and liquidity constraints, Nasdaq listing compliance challenges, clinical trial outcomes, and market acceptance hurdles.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Nexalin Technology, Inc. is headquartered in Houston, Texas, and develops innovative neurostimulation medical devices targeting mental health disorders such as anxiety, insomnia, depression, Alzheimer's disease, and dementia [S1].
- The company’s original Generation 1 (Gen-1) device is a cranial electrotherapy stimulation (CES) device emitting 4 milliamps, classified as FDA Class II for anxiety and insomnia treatment but requiring new FDA applications for marketing and sales in the U.S. [S1].
- Nexalin has developed Generation 2 (Gen-2 SYNC) and Generation 3 (Gen-3 HALO) devices emitting a proprietary 15 milliamp waveform designed for deeper brain stimulation with potential enhanced efficacy and safety [S1].
- Gen-2 SYNC and Gen-3 HALO devices are undergoing FDA Q-submission and pre-submission processes, with clinical trials planned or underway in the U.S., Brazil, and China targeting mental health conditions including insomnia, anxiety, and cognitive disorders [S1].
- The company is developing a virtual clinic platform to enable tele-psychiatry diagnosis and prescription of the Gen-3 HALO headset for home use with physician oversight [S1].
- Nexalin has regulatory approvals for its Gen-2 device in China (NMPA), Brazil, and Oman, and has formed a joint venture in Hong Kong for clinical development and commercialization in China and the region [S1].
- The company acquired PONM, Inc. in Q2 2026, obtaining licensed software and intellectual property to support its AI health platform, with ongoing collaboration for further development [S2].
- As of September 30, 2026, Nexalin had cash and equivalents of $793,139 and short-term investments of $1,500,590, with current assets of $1,891,638 and current liabilities of $2,760,791, resulting in a current ratio of 0.69 and a cash ratio of 0.83 [S2].
- The company reported limited revenue of $78,301 and a net loss of $2,662,068 for the nine months ended September 30, 2026, with basic and diluted EPS of -$3.43 [S2].
- Nexalin completed a one-for-thirty reverse stock split in August 2026 to regain compliance with Nasdaq's minimum bid price requirement and subsequently regained compliance as of September 30, 2026 [N2][N3][S2].
- The company’s continued Nasdaq listing is subject to meeting minimum stockholders’ equity requirements by January 4, 2027, with risks of delisting if not met [S2].
- Nexalin has ongoing financing arrangements including an ATM program and an Any Market Purchase Agreement (AMPA), with recent issuances of common stock and warrants, which may cause dilution [S2].
- The company issued an unsecured promissory note of $1.17 million in August 2026, maturing in February 2027, with mandatory prepayments tied to financing proceeds [S2].
- Nexalin’s clinical trials include pivotal trials for the HALO Clarity device for insomnia and trials for mild traumatic brain injury (mTBI) and PTSD at UCSD, with regulatory approvals and agreements to advance these studies [N5][N6][S1][S2].
- The company acquired an AI health platform in May 2026 to support its HALO Clarity pivotal trial and enhance clinical research capabilities [N4].
- Nexalin appointed Justin Van Fleet as CFO in August 2025 [N8].
- The company has expanded peer-reviewed evidence for its DIFS non-invasive brain stimulation technology [N7].
- Nexalin’s technology uses proprietary waveforms and electrode arrays to deliver non-invasive, safe, and undetectable brain stimulation with no reported adverse side effects [S1].
- The company is engaged with the FDA through Q-submissions and pre-submission meetings to clarify regulatory pathways and clinical trial designs for its devices [S1].
- Nexalin has formed a Military & Government Advisory Board to foster relationships with U.S. federal agencies including the Department of Defense and Veterans Affairs [S1].
Generated 2026-11-13
- S1 | 2026-03-25 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-05 | www.nasdaq.com | Verisk Analytics (VRSK) Surpasses Q3 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/verisk-analytics-vrsk-surpasses-q3-earnings-and-revenue-estimates
- N2 | 2026-10-08 | www.nasdaq.com | Nexalin Technology Regains Compliance With Nasdaq Minimum Bid Price Requirement; Stock Down | https://www.nasdaq.com/articles/nexalin-technology-regains-compliance-nasdaq-minimum-bid-price-requirement-stock-down
- N3 | 2026-08-27 | www.nasdaq.com | Nexalin Announces 1-for-30 Reverse Stock Split; Stock Down | https://www.nasdaq.com/articles/nexalin-announces-1-30-reverse-stock-split-stock-down
- N4 | 2026-05-19 | www.nasdaq.com | Nexalin Acquires AI Health Platform Ahead Of HALO Clarity Pivotal Trial | https://www.nasdaq.com/articles/nexalin-acquires-ai-health-platform-ahead-halo-clarity-pivotal-trial
- N5 | 2026-04-23 | www.nasdaq.com | Nexalin Enters Agreement With Lindus Health To Advance Pivotal Clinical Trial Of HALO Clarity Device | https://www.nasdaq.com/articles/nexalin-enters-agreement-lindus-health-advance-pivotal-clinical-trial-halo-clarity-device
- N6 | 2026-02-24 | www.nasdaq.com | Nexalin Launches Pivotal HALO Clarity Trial To Support Planned FDA Submission For Insomnia | https://www.nasdaq.com/articles/nexalin-launches-pivotal-halo-clarity-trial-support-planned-fda-submission-insomnia
- N7 | 2026-02-03 | www.nasdaq.com | Nexalin Expands Peer-Reviewed Evidence For DIFS Non-Invasive Brain Stimulation | https://www.nasdaq.com/articles/nexalin-expands-peer-reviewed-evidence-difs-non-invasive-brain-stimulation
- N8 | 2025-08-01 | www.nasdaq.com | Nexalin Technology Appoints Justin Van Fleet As CFO | https://www.nasdaq.com/articles/nexalin-technology-appoints-justin-van-fleet-cfo
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


